Diego Annesi

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

Anna Maria Di Giacomo, Paolo A. Ascierto, Lorenzo Pilla et al. · The Lancet Oncology · 2012 · 281 citations

Medicine, Oncology, Pharmacology +13

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

Luana Calabrò, Aldo Morra, Ester Fonsatti et al. · The Lancet Respiratory Medicine · 2015 · 204 citations

Medicine, Oncology, Pharmacology +11

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

Anna Maria Di Giacomo, Paolo A. Ascierto, Paola Queirolo et al. · Annals of Oncology · 2014 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients

Cristina Maccalli, Diana Giannarelli, Carla Chiarucci et al. · OncoImmunology · 2017 · 59 citations · Full text

Life Sciences, Immunology, Oncology +17

Towards more reliable measurements of sound absorption coefficient in reverberation rooms: An Inter-Laboratory Test

Chiara Scrosati, Francesco Martellotta, Francesco Pompoli et al. · Applied Acoustics · 2020 · 32 citations · Full text

Natural Sciences, Building Science, Physics +15